The global Protein A Resin market size was estimated at USD 1.12 billion in 2023 and is projected to reach USD 1.89 billion in 2030 at a CAGR of 7.8% during the forecast period 2024-2030.
The demand for monoclonal antibodies has surged significantly during the COVID-19 pandemic due to their critical role in diagnosing and treating the virus. This increase has driven manufacturers to accelerate the development and production of monoclonal antibodies to meet the growing patient needs. Protein A resins, essential for the purification of these antibodies, have consequently seen heightened demand. The urgency for COVID-19 vaccines has also contributed to this trend, alongside increased investments in the biopharmaceutical industry aimed at combating the pandemic.
However, the COVID-19 pandemic also disrupted global supply chains, impacting the availability of raw materials and manufacturing components, which negatively affected the protein A resins market. Research and development activities faced delays due to resource reallocation towards COVID-19-related projects, compounding these challenges. Despite these disruptions, the rising prevalence of chronic diseases, such as cancer, has sustained the demand for monoclonal antibodies, bolstering the need for efficient purification processes using protein A resins.
Monoclonal antibodies are pivotal in modern drug development, particularly for oncology, autoimmune, and infectious diseases, necessitating robust purification methods. This has led to increased demand for protein A resins. For instance, a 2023 report by the Society of Biological Engineering Journal highlighted the surge in protein A resin demand due to the biopharmaceutical industry's need for efficient purification methods.
The high costs associated with protein A resins remain a challenge for market growth. However, manufacturers are investing in research and development to innovate and develop advanced protein A chromatography resins or alternatives. Strategies like mergers, acquisitions, collaborations, and product launches are employed to expand regional presence and diversify product offerings. Notable examples include Purolite Life Sciences' launch of next-generation chromatography resins in 2021 and Thermo Fisher Scientific's collaboration with Newomics to develop a novel LC-MS platform.
The pharmaceutical and biopharmaceutical companies are anticipated to dominate the protein A resin market, primarily due to their extensive use of proteins in drug discovery and development. Protein analysis is crucial for target identification, efficacy and toxicity biomarker identification, and understanding drug mechanisms, which is fueling market growth amidst numerous ongoing drug development projects globally. Government funding and technological advancements in analytical instruments further drive this segment's growth. Increasing life science R&D expenditure, drug discovery progress, and the adoption of chromatography are key drivers. For instance, Merck's investment in an advanced research centre in Germany and Otsuka Pharmaceutical's Osaka Research Centre underline the industry's commitment to antibody research, thereby boosting protein A resin demand.
Additionally, strategic agreements and expansions, such as Purolite's extended agreement with Repiligen Corporation and Ecolab Inc.'s new biologics resin manufacturing facility, highlight the industry's response to the growing demand. The competitive and fragmented nature of the protein A resin market sees major players continually introducing innovative products and forming partnerships to maintain a market edge. This dynamic environment, coupled with ongoing R&D, underscores the sector's robust growth trajectory, making protein A resins indispensable in pharmaceutical and biopharmaceutical applications.
